Home › Pleural Effusion › NCT07929584

A Study to Establish the Diagnostic Value of the EPISEEK-MPE Liquid Biopsy Assay to Identify Cancer in Pleural Effusion Samples.

Development of a Molecular Assay to Diagnose Malignant Pleural Effusions

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult patients having pleural fluid drained for clinical care (thoracentesis or chest tube placement)
* Consent to have pleural fluid sample used for research

Exclusion Criteria:

\- Insufficient fluid available following clinical drainage procedure

About the study

The goal of this study is to evaluate the EPISEEK-MPE laboratory test for diagnosis of malignant (cancerous) pleural effusions verses pleural effusions caused by a non-cancer condition. The study uses excess samples drained from around the lung as part of a patient's regular care. The main questions the study aims to answer are:

1. Is the EPISEEK-MPE test reliable to detect cancer cells and aid in the diagnosis of malignant pleural effusions? 2. Do age, race, gender and ethnicity change the reliability of the EPISEEK-MPE test? 3. Can the results of the EPISEEK-MPE test predict which patients have a better chance of survival than others?

Participants will be asked to donate a small portion of the excess fluid drained from around the lung for research. Participants will also give permission to collect data from the medical records.

Sponsor: University of Arizona · Participants: 625 · Started: Jan 8, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07929584

Locations in the U.S.

Conditions

• Pleural Effusion
• Malignant Pleural Effusion

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.